IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i12p7233-d837702.html
   My bibliography  Save this article

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Author

Listed:
  • Fabrizio Bert

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy)

  • Giacomo Scaioli

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy)

  • Lorenzo Vola

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy)

  • Davide Accortanzo

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy)

  • Giuseppina Lo Moro

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy)

  • Roberta Siliquini

    (Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
    AOU City of Health and Science of Turin, 10126 Turin, Italy)

Abstract

The need for an anti-COVID-19 booster dose posed an organizational challenge for health policy makers worldwide. Therefore, this study aimed to explore the health policies regarding the booster dose through an overview of recommendations issued in high-income countries. Between 10 November and 16 December 2021, the authors searched for state-level official documents about the offer of the booster dose, considering the 43 countries belonging to the European Union (EU) or the Organisation for Economic Co-operation and Development (OECD). Mainly due to the lack of English translation, 15 countries were excluded. A total of 135 documents were selected. Almost all the countries started administering the booster dose between September and November 2021. The most used products were mRNA vaccines, followed by Vaxzevria-AstraZeneca and Jcovden-Janssen/Johnson & Johnson. All countries established criteria to define categories of individuals to be vaccinated as a priority. A six/five-months interval was the main choice for general population vaccinated with mRNA vaccines, while shorter intervals were chosen for vulnerable individuals or other vaccines. Despite diversities related to the differences in health systems, economical resources, and population numbers, and the need to adapt all these factors to a massive vaccination campaign, a progressive convergence towards the same vaccination policies was highlighted.

Suggested Citation

  • Fabrizio Bert & Giacomo Scaioli & Lorenzo Vola & Davide Accortanzo & Giuseppina Lo Moro & Roberta Siliquini, 2022. "Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries," IJERPH, MDPI, vol. 19(12), pages 1-16, June.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7233-:d:837702
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/12/7233/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/12/7233/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Ewen Callaway, 2021. "COVID vaccine boosters: the most important questions," Nature, Nature, vol. 596(7871), pages 178-180, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jadsada Kunno & Busaba Supawattanabodee & Chavanant Sumanasrethakul & Chuthamat Kaewchandee & Wachiraporn Wanichnopparat & Krit Prasittichok, 2022. "The Relationship between Attitudes and Satisfaction Concerning the COVID-19 Vaccine and Vaccine Boosters in Urban Bangkok, Thailand: A Cross-Sectional Study," IJERPH, MDPI, vol. 19(9), pages 1-11, April.
    2. Miguel Junior Sordi Bortolini & Bernardo Petriz & José Roberto Mineo & Rafael de Oliveira Resende, 2022. "Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups," IJERPH, MDPI, vol. 19(3), pages 1-10, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7233-:d:837702. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.